384 related articles for article (PubMed ID: 25036883)
1. Immunotherapy for ovarian cancer: recent advances and perspectives.
Zsiros E; Tanyi J; Balint K; Kandalaft LE
Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy opportunities in ovarian cancer.
Chu CS; Kim SH; June CH; Coukos G
Expert Rev Anticancer Ther; 2008 Feb; 8(2):243-57. PubMed ID: 18279065
[TBL] [Abstract][Full Text] [Related]
3. Opportunities in immunotherapy of ovarian cancer.
Coukos G; Tanyi J; Kandalaft LE
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i11-i15. PubMed ID: 27141063
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in ovarian cancer.
Krishnan V; Berek JS; Dorigo O
Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
De Felice F; Marchetti C; Palaia I; Musio D; Muzii L; Tombolini V; Panici PB
J Immunol Res; 2015; 2015():191832. PubMed ID: 26236750
[TBL] [Abstract][Full Text] [Related]
6. Emerging immunotherapies in ovarian cancer.
Ojalvo LS; Nichols PE; Jelovac D; Emens LA
Discov Med; 2015 Sep; 20(109):97-109. PubMed ID: 26463091
[TBL] [Abstract][Full Text] [Related]
7. A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan.
Fujimoto K; Tomonaga M; Goto S
Anticancer Res; 2006; 26(6A):4015-8. PubMed ID: 17195451
[TBL] [Abstract][Full Text] [Related]
8. The immunotherapy of patients with ovarian cancer.
Hwu P; Freedman RS
J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
[TBL] [Abstract][Full Text] [Related]
9. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer from an immune perspective.
Zakharia Y; Rahma O; Khleif SN
Radiat Res; 2014 Aug; 182(2):239-51. PubMed ID: 25036981
[TBL] [Abstract][Full Text] [Related]
11. Past, present and future targets for immunotherapy in ovarian cancer.
Schwab CL; English DP; Roque DM; Pasternak M; Santin AD
Immunotherapy; 2014; 6(12):1279-93. PubMed ID: 25524384
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell immunotherapy in ovarian cancer.
Stiff PJ; Czerlanis C; Drakes ML
Expert Rev Anticancer Ther; 2013 Jan; 13(1):43-53. PubMed ID: 23259426
[TBL] [Abstract][Full Text] [Related]
13. Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
[TBL] [Abstract][Full Text] [Related]
14. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.
Adams M; Navabi H; Croston D; Coleman S; Tabi Z; Clayton A; Jasani B; Mason MD
Vaccine; 2005 Mar; 23(17-18):2374-8. PubMed ID: 15755631
[TBL] [Abstract][Full Text] [Related]
15. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?
Bronte G; Cicero G; Sortino G; Pernice G; Catarella MT; D'Alia P; Cusenza S; Lo Dico S; Bronte E; Sprini D; Midiri M; Firenze A; Fiorentino E; Bazan V; Rolfo C; Russo A
Expert Opin Biol Ther; 2014 Jan; 14(1):103-14. PubMed ID: 24313266
[TBL] [Abstract][Full Text] [Related]
17. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.
Wefers C; Lambert LJ; Torensma R; Hato SV
Gynecol Oncol; 2015 May; 137(2):335-42. PubMed ID: 25727651
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ventriglia J; Paciolla I; Pisano C; Cecere SC; Di Napoli M; Tambaro R; Califano D; Losito S; Scognamiglio G; Setola SV; Arenare L; Pignata S; Della Pepa C
Cancer Treat Rev; 2017 Sep; 59():109-116. PubMed ID: 28800469
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies.
Nicodemus CF; Schultes BC; Hamilton BL
Expert Rev Vaccines; 2002 Jun; 1(1):35-48. PubMed ID: 12908511
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
Yigit R; Massuger LF; Figdor CG; Torensma R
Gynecol Oncol; 2010 May; 117(2):366-72. PubMed ID: 20144842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
